Detalhe da pesquisa
1.
Addressing disparities in biologic drug development in the United States.
J Allergy Clin Immunol
; 148(5): 1154-1156, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34530019
2.
Cost considerations for clinicians prescribing biologic drugs: Who pays?
J Allergy Clin Immunol
; 146(2): 266-269, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32325143
3.
Factors Associated With Asthma Biologic Prescribing and Primary Adherence Among Adults in a Large Health System.
J Allergy Clin Immunol Pract
; 11(6): 1834-1842.e4, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36907354
4.
Boxed Warnings and Off-Label Use of Allergy Medications: Risks, Benefits, and Shared Decision Making.
J Allergy Clin Immunol Pract
; 10(12): 3057-3063, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36064185
5.
Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease.
Am J Health Syst Pharm
; 78(13): 1184-1194, 2021 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-33821890
6.
Is specialty patient care affected by exclusivity?
Am J Health Syst Pharm
; 76(22): 1821-1822, 2019 10 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31549999
7.
US Propofol Drug Shortages: A Review of the Problem and Stakeholder Analysis.
Am Health Drug Benefits
; 6(4): 171-5, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24991355